Thermo Fisher Scientific Inc. $TMO Shares Sold by Candriam S.C.A.

Candriam S.C.A. lessened its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 20.1% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 337,473 shares of the medical research company’s stock after selling 84,881 shares during the period. Thermo Fisher Scientific comprises 0.8% of Candriam S.C.A.’s investment portfolio, making the stock its 22nd biggest holding. Candriam S.C.A.’s holdings in Thermo Fisher Scientific were worth $136,838,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of TMO. CBIZ Investment Advisory Services LLC boosted its holdings in Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at $30,000. Keystone Global Partners LLC purchased a new stake in Thermo Fisher Scientific in the first quarter valued at $31,000. DiNuzzo Private Wealth Inc. grew its holdings in shares of Thermo Fisher Scientific by 406.7% during the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 140.6% in the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 45 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the transaction, the vice president directly owned 14,145 shares in the company, valued at approximately $8,085,564.90. This trade represents a 41.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $566.10, for a total transaction of $4,104,225.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at $64,400,668.20. This trade represents a 5.99% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 46,645 shares of company stock valued at $25,825,699 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

TMO has been the subject of several research reports. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research report on Thursday, July 24th. Cowen reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Citigroup boosted their price target on Thermo Fisher Scientific from $500.00 to $580.00 and gave the company a “neutral” rating in a research report on Thursday, October 23rd. Morgan Stanley increased their price objective on Thermo Fisher Scientific from $560.00 to $656.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 28th. Finally, Wells Fargo & Company upped their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Trading Up 0.3%

NYSE:TMO opened at $588.53 on Thursday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50. The stock has a fifty day moving average price of $524.35 and a two-hundred day moving average price of $465.87. The stock has a market capitalization of $221.12 billion, a price-to-earnings ratio of 34.00, a PEG ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has approved a share repurchase program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 2.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.